EA202090193A1 - Кристаллическая форма n-[1-(5-цианопиридин-2-илметил)-1h-пиразол-3-ил]-2-[4-(1-трифторметилциклопропил)фенил]ацетамида - Google Patents
Кристаллическая форма n-[1-(5-цианопиридин-2-илметил)-1h-пиразол-3-ил]-2-[4-(1-трифторметилциклопропил)фенил]ацетамидаInfo
- Publication number
- EA202090193A1 EA202090193A1 EA202090193A EA202090193A EA202090193A1 EA 202090193 A1 EA202090193 A1 EA 202090193A1 EA 202090193 A EA202090193 A EA 202090193A EA 202090193 A EA202090193 A EA 202090193A EA 202090193 A1 EA202090193 A1 EA 202090193A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- crystal form
- crystalline forms
- type calcium
- trifluoromethylcyclopropyl
- cyanopyridin
- Prior art date
Links
- 102000003691 T-Type Calcium Channels Human genes 0.000 abstract 2
- 108090000030 T-Type Calcium Channels Proteins 0.000 abstract 2
- -1 5-cyanopyridin-2-ylmethyl Chemical group 0.000 abstract 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Изобретение относится к кристаллическим формам N-[1-(5-цианопиридин-2-илметил)-1H-пиразол-3-ил]-2-[4-(1-трифторметилциклопропил)фенил]ацетамида, к фармацевтическим композициям, содержащим указанные кристаллические формы, и к их применению в качестве блокаторов кальциевых каналов T-типа при лечении или профилактике заболеваний или расстройств, в которых участвуют кальциевые каналы T-типа.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2017066806 | 2017-07-05 | ||
PCT/EP2018/068087 WO2019008034A1 (en) | 2017-07-05 | 2018-07-04 | CRYSTALLINE FORM OF N- [1- (5-CYANO-PYRIDIN-2-YLMETHYL) -1H-PYRAZOL-3-YL] -2- [4- (1-TRIFLUOROMETHYL-CYCLOPROPYL) -PHENYL] -ACETAMIDE |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202090193A1 true EA202090193A1 (ru) | 2020-06-03 |
Family
ID=63079885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090193A EA202090193A1 (ru) | 2017-07-05 | 2018-07-04 | Кристаллическая форма n-[1-(5-цианопиридин-2-илметил)-1h-пиразол-3-ил]-2-[4-(1-трифторметилциклопропил)фенил]ацетамида |
Country Status (16)
Country | Link |
---|---|
US (2) | US11059803B2 (ru) |
EP (1) | EP3649117A1 (ru) |
JP (2) | JP2020525475A (ru) |
KR (1) | KR102645911B1 (ru) |
CN (1) | CN110831932A (ru) |
AU (1) | AU2018296423B2 (ru) |
BR (1) | BR112020000099A2 (ru) |
CA (1) | CA3067489A1 (ru) |
CL (1) | CL2020000002A1 (ru) |
EA (1) | EA202090193A1 (ru) |
IL (1) | IL271764B2 (ru) |
MA (1) | MA50972A (ru) |
PH (1) | PH12020500040A1 (ru) |
SG (1) | SG11201912881SA (ru) |
UA (1) | UA126582C2 (ru) |
WO (1) | WO2019008034A1 (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110072521B (zh) | 2016-12-16 | 2022-11-29 | 爱杜西亚药品有限公司 | 包含t型钙通道阻断剂的药物组合 |
US10899695B2 (en) | 2017-02-06 | 2021-01-26 | Idorsia Pharmaceuticals Ltd | Process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes |
KR102645911B1 (ko) * | 2017-07-05 | 2024-03-08 | 이도르시아 파마슈티컬스 리미티드 | N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세타미드의 결정질 형태 |
WO2021123949A1 (en) | 2019-12-20 | 2021-06-24 | Idorsia Pharmaceuticals Ltd | Pharmaceutical compositions comprising n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide |
WO2023240205A1 (en) | 2022-06-10 | 2023-12-14 | Neurocrine Biosciences, Inc. | Deuterated compounds |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA40281B1 (fr) | 2014-06-03 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t |
MX367519B (es) | 2014-09-15 | 2019-08-26 | Idorsia Pharmaceuticals Ltd | Compuestos triazolicos como bloqueadores de canales de calcio tipo t. |
CN110072521B (zh) | 2016-12-16 | 2022-11-29 | 爱杜西亚药品有限公司 | 包含t型钙通道阻断剂的药物组合 |
US10899695B2 (en) | 2017-02-06 | 2021-01-26 | Idorsia Pharmaceuticals Ltd | Process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes |
KR102645911B1 (ko) * | 2017-07-05 | 2024-03-08 | 이도르시아 파마슈티컬스 리미티드 | N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세타미드의 결정질 형태 |
-
2018
- 2018-07-04 KR KR1020207002894A patent/KR102645911B1/ko active IP Right Grant
- 2018-07-04 BR BR112020000099-0A patent/BR112020000099A2/pt active Search and Examination
- 2018-07-04 CA CA3067489A patent/CA3067489A1/en active Pending
- 2018-07-04 IL IL271764A patent/IL271764B2/en unknown
- 2018-07-04 EP EP18749304.4A patent/EP3649117A1/en active Pending
- 2018-07-04 CN CN201880044771.7A patent/CN110831932A/zh active Pending
- 2018-07-04 UA UAA202000506A patent/UA126582C2/uk unknown
- 2018-07-04 JP JP2019572102A patent/JP2020525475A/ja active Pending
- 2018-07-04 AU AU2018296423A patent/AU2018296423B2/en active Active
- 2018-07-04 US US16/628,618 patent/US11059803B2/en active Active
- 2018-07-04 EA EA202090193A patent/EA202090193A1/ru unknown
- 2018-07-04 MA MA050972A patent/MA50972A/fr unknown
- 2018-07-04 WO PCT/EP2018/068087 patent/WO2019008034A1/en unknown
- 2018-07-04 SG SG11201912881SA patent/SG11201912881SA/en unknown
-
2020
- 2020-01-02 CL CL2020000002A patent/CL2020000002A1/es unknown
- 2020-01-03 PH PH12020500040A patent/PH12020500040A1/en unknown
-
2021
- 2021-06-11 US US17/345,844 patent/US11555025B2/en active Active
-
2023
- 2023-06-26 JP JP2023104050A patent/JP2023123679A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3067489A1 (en) | 2019-01-10 |
KR102645911B1 (ko) | 2024-03-08 |
EP3649117A1 (en) | 2020-05-13 |
IL271764B1 (en) | 2023-06-01 |
SG11201912881SA (en) | 2020-01-30 |
US20200165221A1 (en) | 2020-05-28 |
IL271764B2 (en) | 2023-10-01 |
AU2018296423B2 (en) | 2022-07-28 |
US11059803B2 (en) | 2021-07-13 |
PH12020500040A1 (en) | 2020-10-12 |
WO2019008034A1 (en) | 2019-01-10 |
MA50972A (fr) | 2020-10-14 |
AU2018296423A1 (en) | 2020-02-20 |
UA126582C2 (uk) | 2022-11-02 |
US20210300894A1 (en) | 2021-09-30 |
KR20200018698A (ko) | 2020-02-19 |
IL271764A (en) | 2020-02-27 |
JP2020525475A (ja) | 2020-08-27 |
CN110831932A (zh) | 2020-02-21 |
CL2020000002A1 (es) | 2020-07-31 |
US11555025B2 (en) | 2023-01-17 |
JP2023123679A (ja) | 2023-09-05 |
BR112020000099A2 (pt) | 2020-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202090193A1 (ru) | Кристаллическая форма n-[1-(5-цианопиридин-2-илметил)-1h-пиразол-3-ил]-2-[4-(1-трифторметилциклопропил)фенил]ацетамида | |
EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
PE20180160A1 (es) | Sulfonilureas y compuestos relacionados y uso de estos | |
EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
EA201692049A1 (ru) | Гетероарилзамещенные гетероциклилсульфоны | |
EA201490922A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
EA201892407A1 (ru) | Кристаллические формы n-[2-(3-гидрокси-3-метилбутил)-6-(2-гидроксипропан-2-ил)-2н-индазол-5-ил]-6-(трифторметил)пиридин-2-карбоксамида | |
EA201692007A1 (ru) | Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений | |
EA201790892A1 (ru) | Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина | |
ATE527243T1 (de) | Calciumkanal-antagonisten vom typ chinazolinon t | |
EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
EA201991428A1 (ru) | Фармацевтическая комбинация, содержащая блокатор кальциевых каналов т-типа | |
PE20170129A1 (es) | Compuestos de pirazol y su uso como bloqueadores de los canales de calcio tipo t | |
EA201692474A1 (ru) | Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2 | |
EA201990678A1 (ru) | Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2 | |
EA201890800A1 (ru) | Соединения и композиции для лечения глазных расстройств | |
EA202091428A1 (ru) | Замещенные амиды ii пирролидина | |
EA201692008A1 (ru) | Замещенные сконденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений | |
CY1124056T1 (el) | Κρυσταλλικες μορφες της μηλεϊνικης 1-((2r, 4r)-2-(1η-βενζο[d] iμιδαζολ-2-υλο)-1-μεθυλοπιπεριδιν-4-υλο)-3-(4-κυανοφαινυλ) ουριας | |
EA201692260A1 (ru) | Соединения 1,3,4-тиадиазола и их применение в лечении рака | |
EA201792281A1 (ru) | Твердые формы 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4- метилциклогексиламино)пиримидин-5-карбоксамида, его композиции и способы его применения | |
EA202192320A1 (ru) | Кристаллическая форма моногидрата 1-(1-оксо-1,2-дигидроизохинолин-5-ил)-5-(трифторметил)-n-[2-(трифторметил)пиридин-4-ил]-1h-пиразол-4-карбоксамида | |
EA201990399A1 (ru) | Соединения, композиции и их применение | |
MX2018004217A (es) | Tetrahidropiranilsulfonas sustituidas con pirazolilo. | |
EA201792558A1 (ru) | Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль |